Sunitinib first-line

May 2017

Cancer

Country of origin: UK

In new guidance issued by NICE, Sunitinib is recommended as a possible first drug treatment for people with advanced and/or metastatic renal cell carcinoma if: immunotherapy (for example, interferon alfa) would be suitable for them and they are mobile and can do light housework or office work. When assessing people with disabilities, healthcare professionals should bear in mind that a person?s disability might also affect their level of physical activity. They should make adjustments for this.

Specialists should not stop prescribing sunitinib for people who were already taking it when the guidance was issued. These people should be able to carry on taking sunitinib until they and their specialist decide that it is the right time to stop treatment.

NICE has been appraising the use of bevacizumab, sorafenib, sunitinib and temsirolimus for the treatment of advanced and/or metastatic renal cell carcinoma.
Following the independent advisory Committee meeting on 14 January 2009 NICE has decided to split this appraisal in two in order to get guidance out to the NHS as quickly as possible.

NICE is also appraising the use of bevacizumab, sorafenib and temsirolimus for first-line treatment options for advanced and/or metastatic renal cell carcinoma and the two drugs also licensed for second-line treatment of advanced or metastatic renal cell carcinoma, sorafenib and sunitinib, guidance is expected to be published later this year.

The guidance is available online.

Resources

Cancer statistics: availability and location July 2018 Document aims to provide an overview about cancer statistics, including information on statistics publicly available and...
inPractice® Oncology July 2018 inPractice® Oncology is the only point-of-care clinical reference designed to meet the unique needs of specialists. Full...
Cancer Research Network Measures March 2018 Following a period of consultation Cancer Research Network Measures have been issued by the Department of Health as part of...
Orlive Surgical Broadcasts February 2018 Orlive is a trusted world resource in surgical broadcasting for physians, surgeons and caregivers.
Cancer.net mobile by ASCO January 2018 The Cancer.net mobile app by ASCO provides info on 120 types of cancer, including treatment information, managing side...
Chemo Calendar January 2018 Chemo Calendar app by Health Monitor Network can track the patient’s symptoms. It captures key symptoms like temperature,...
Cancer Navigator January 2018 Cancer Navigator app was developed by MD Acuity, LLC. The app tracks symptoms during cancer treatment in a graphic...
Oncology Nurse Advisor January 2018 Oncology Nurse Advisor is a free, simple to use, medical app that offers oncology nurses the latest news and trends....
Breast Cancer Survivor January 2018 Survivorship encompasses a range of lifestyle approaches to improve wellbeing and survival after a diagnosis of cancer....
Cancer Emergency Response Tool January 2018 The Cancer Emergency Response Tool (CERT) allows cancer patients to rapidly and effectively manage chemotherapy toxicity...
Search by Keyword